New data from Fasenra and Tezspire trials demonstrate AstraZeneca biologics progress towards achieving remission in severe asthma New EXACOS-CV data uncover increased cardiopulmonary risk following COPD exacerbations London – AstraZeneca will present new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the European Respiratory Society (ERS) International Congress 2023, in Milan, Italy from …